GLP-1 receptor agonists for Parkinson's disease (Protocol) by Mulvaney, Caroline A. et al.
Cochrane Database of Systematic Reviews
GLP-1 receptor agonists for Parkinson’s disease (Protocol)
Mulvaney CA, Duarte GS, Menon S, Handley J, Emsley HC
Mulvaney CA, Duarte GS, Menon S, Handley J, Emsley HC.
GLP-1 receptor agonists for Parkinson’s disease.
Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No.: CD012990.
DOI: 10.1002/14651858.CD012990.
www.cochranelibrary.com
GLP-1 receptor agonists for Parkinson’s disease (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iGLP-1 receptor agonists for Parkinson’s disease (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
GLP-1 receptor agonists for Parkinson’s disease
Caroline A Mulvaney1 , Gonçalo S Duarte2,3, Suresh Menon4 , Joel Handley1,5, Hedley C.A. Emsley1,6
1Lancaster Medical School, Lancaster University, Lancaster, UK. 2Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de
Medicina de Lisboa, Lisboa, Portugal. 3Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisboa, Portugal. 4Department
of Medicine, McMaster University, Hamilton, Canada. 5Department of Neurology, Salford Royal Hospital, Salford, UK. 6Department
of Neurology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK
Contact address: Caroline A Mulvaney, Lancaster Medical School, Lancaster University, Lancaster, LA1 4YG, UK.
c.mulvaney@lancaster.ac.uk, caroline.mulvaney@nottingham.ac.uk.
Editorial group: Cochrane Movement Disorders Group.
Publication status and date: New, published in Issue 3, 2018.
Citation: Mulvaney CA, Duarte GS, Menon S, Handley J, Emsley HC. GLP-1 receptor agonists for Parkinson’s disease. Cochrane
Database of Systematic Reviews 2018, Issue 3. Art. No.: CD012990. DOI: 10.1002/14651858.CD012990.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the effectiveness and safety of GLP-1 receptor agonists for Parkinson’s disease.
We will differentiate, as far as possible between neuroprotective and symptomatic effects.
B A C K G R O U N D
Description of the condition
Parkinson’s disease (PD) is the second commonest neurodegen-
erative disorder after Alzheimer’s disease (AD), affecting approx-
imately 0.5% of the population over 60 years of age in indus-
trialised countries (Pringhseim 2014). It is caused by the loss of
dopamine-producing nerve cells in the part of the brain called the
substantia nigra. Dopamine functions as a neurotransmitter and
plays a key role in motor control. It is not known what causes the
loss of these dopamine-producing nerve cells.
PD is a long-term, progressive disorder which causes significant
disability. The symptoms generally develop slowly, typically over
10 to 15 years. PD is characterised by motor features (problems
with movement) that include a slowness of movement, shaking at
rest, muscular rigidity and postural instability (Kalia 2015), and
a variety of non-motor features which include a loss of sense of
smell, and sleep and psychiatric dysfunction, including depression,
anxiety and dementia. As the disease progresses and treatment-
resistant motor and non-motor features dominate, falls, freezing
of gait, choking, urinary incontinence and dementia are common
(Hely 2005; Hely 2008).
PD shows an increasing incidence with age and is more common
in men than women (Hirsch 2016). Risk factors for PD include
exposure to pesticides and other environmental chemicals (often
experienced by agricultural workers), high consumption of dairy
products, a diagnosis of melanoma and traumatic brain injury
(Ascherio 2016; de Lau 2006). Protective factors include the use
of tobacco, consumption of coffee, caffeine and tea, higher plasma
concentration of urates (salts of uric acid), physical activity and
non-steroidal anti-inflammatory drugs (Ascherio 2016).
At present, there are no effective disease modifying or neuropro-
tective interventions: current therapies for PD treat the symptoms
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only. Available therapies include levodopa which is converted in
the brain (as well as in the periphery) to dopamine, and dopamine
receptor agonists that stimulate dopamine receptors.
Typically, PD is defined pathologically by prominent dopamin-
ergic neuron loss and the presence of Lewy bodies containing α-
synuclein in the brain. It is increasingly recognised that the neu-
rodegenerative process in PD is complex and multifactorial, and
is also likely to involve mitochondrial dysfunction and oxidative
stress (Abou-Sleiman 2006), inflammation (Collins 2012), blood-
brain barrier dysfunction (Gray 2015), and neurovascular changes
(Al-Bachari 2017). Such factors are likely to have treatment and
prognostic implications. Vascular comorbidity (including prior
stroke, TIA or more than two vascular risk factors), for instance,
has recently been found to be significantly associated with cogni-
tive and gait impairment in early PD (Malek 2016).
Description of the intervention
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of
drugs that are licensed for the treatment of Type 2 diabetes (Baggio
2007; Campbell 2013; Doyle 2003; Holst 2004). An agonist acts
by binding to a receptor (a protein molecule that is the target for
the drug) which causes some form of cellular response (Pleuvry
2004). For people with Type 2 diabetes, GLP-1 receptor agonists
work by stimulating the GLP-1 receptors in the pancreas, which
triggers the release of insulin. However, GLP-1 receptors have also
been found in the brain and thusGLP-1 receptor agonistsmay also
have a role to play in the treatment of PD. Insulin signalling in the
brain plays a key role in neuronal metabolism, repair and synap-
tic efficacy (Freiherr 2013; Ghasemi 2013; van der Heide 2006).
Insulin activates growth factor receptors on neurons that con-
trol energy utilisation, cell repair, mitochondrial function, synapse
growth and functionality. Several classic second messenger cell sig-
nalling pathways are activated while apoptotic (programmed cell
death) cell signalling is inhibited (Holscher 2014). It has been
shown that insulin signalling is desensitised in the brains of pa-
tients with PD (Aviles-Olmos 2013a; Moroo 1994;Morris 2011),
which may explain why Type 2 diabetes has been identified as a
risk factor for the development of PD (Hu 2007; Schernhammer
2011; Sun 2012; Wahlqvist 2012). GLP-1 receptor agonists are
administered by subcutaneous injection.
How the intervention might work
GLP-1 activates the same key growth factor cell signalling cascades
as insulin, and therefore compensates for the loss of insulin sig-
nalling (Jalewa 2016). Protease-resistant analogues of GLP-1 have
shown neuroprotective effects in animal models of AD (Bomfim
2012; Li 2010; McClean 2011), and resensitise insulin signalling
in the brain (Long-Smith 2013). Furthermore, previous studies
found that GLP-1 receptor agonists also have neuroprotective ef-
fects in animal models of PD. The GLP-1 mimetic (molecule re-
sembling GLP-1), exendin-4, protected motor activity, dopamine
levels in the striatum, reduced chronic inflammation and oxidative
stress (Harkavyi 2008; Li 2009; Liu 2015a; Zhang 2015). In the
1-methyl-4-phenyl-1,2,3,6-tetrahydropypridine (MPTP) mouse
model of PD, GLP-1 mimetics protected the brain from aspects
of the MPTP-induced pathology, such as motor impairment, in-
crease in α-synuclein levels, chronic inflammation in the brain,
loss of dopaminergic neurons, oxidative stress and growth factor
expression (Ji 2016; Li 2016; Liu 2015a; Liu 2015b; Zhang 2015).
The GLP-1 mimetics liraglutide and lixisenatide are more effec-
tive than the first-generation drug exendin-4. The newer GLP-
1 mimetics improve motor co-ordination and activity, and both
drugs rescue the expression of tyrosine hydroxylase, a key enzyme
in dopamine synthesis (Liu 2015a).
A challenge for clinical trials of neurodegenerative diseases such as
PD is to differentiate between the disease-modifying effects and
symptomatic effects of any therapeutic agent. Scales used in clin-
ical assessment of PD to measure changes in, for example, motor
impairment or quality of life, are unable to distinguish between
symptomatic and disease-modifying effects of a treatment. Thus,
in order for any novel, potential drug to demonstrate disease mod-
ification there needs to be evidence that the drug, when adminis-
tered for a period of time, stops disease progression. This can be
demonstrated in a clinical trial by an absence of deterioration in
clinical outcomemeasures by comparisonwith a control or placebo
group. leicesershire schools between treatment groups are indeed
evidence of disease modification rather than symptomatic effects
(McGhee 2013). Changes in relevant biomarkers, such as presy-
naptic striatal dopamine transporter (DAT) binding as assessed by
[¹²³I]FP-CIT single photon emission CT (DaTSCAN) examina-
tions, would provide additional evidence of disease modification.
In addition, confounders may influence therapeutic effects. For
example, while there is evidence that GLP-1 can cause weight loss
(Vilsbøll 2012), it is known that the amount of levodopa and its
maximum concentration in plasma are negatively correlated with
body weight (Müller 2000), and consequently weight loss can lead
to an increase in the effectiveness of levodopa. Thus an awareness
of potential changes in weight loss due to GLP-1 and subsequent
therapeutic effects on PD is essential in a study of GLP-1 receptor
agonists.
Why it is important to do this review
Recent advances in understanding of the neuroprotective effects
of incretin-based therapies, including GLP-1 receptor agonists,
mean that there is considerable interest in their potential utility
as repurposed treatments for several neurodegenerative disorders,
including PD. People with PD treated with exenatide in an open-
label clinical trial showed clinical benefit (Aviles-Olmos 2013b),
with subsequent evidence of significant improvement in motor
features 12 months after stopping exenatide (Aviles-Olmos 2014).
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Similarly, a recent double-blind clinical trial of people with PD
found that those treated with exenatide showed improved motor
features 60 weeks after coming off the medication, while motor
features for those on placebo had worsened (Athauda 2017). It
is therefore timely to undertake this review of GLP-1 receptor
agonists for PD, as this will provide a summary of the current state
of the evidence, as well as providing a platform for updating the
evidence base as future studies emerge.
O B J E C T I V E S
To evaluate the effectiveness and safety of GLP-1 receptor agonists
for Parkinson’s disease.
We will differentiate, as far as possible between neuroprotective
and symptomatic effects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include published and unpublished, parallel-designed,
randomized controlled trials (RCTs). We will exclude non-parallel
study designs, that is cross-over trials, due to uncertainty about
whether this type of study design is appropriate to study people
with PD (Higgins 2011).
Types of participants
We will include trials with a study population of adults (i.e. ≥
18 years of age), in any setting, with a clinical diagnosis made by
any physician, specialist or otherwise, of PD according to the UK
Parkinson’sDisease Society BrainBank diagnostic criteria (Hughes
1992), or other equivalent clinical diagnostic criteria, or on the
basis of clinical neurological assessment. We will include people at
all stages of the disease. Participants may have medical conditions
in addition to PD.
We will apply no restrictions based on the number of participants
recruited to trials, or the number of recruitment centres.
Types of interventions
We will include studies that involve delivery of GLP-1 receptor
agonists with no restrictions on dosage or duration of treatment.
We will assess the following comparisons:
1. GLP-1 receptor agonists versus conventional PD treatment;
2. GLP-1 receptor agonists versus placebo intervention; and
3. GLP-1 receptor agonists versus no treatment.
Types of outcome measures
Primary outcomes
1. PD motor impairment measured using the Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS) subscale Part
III (Fahn 1987).
2. Health-related quality of life measured using a validated
scale such as:
i) Parkinson’s Disease Questionnaire (PDQ-39) (Peto
1995), or short form PDQ-8 (Jenkinson 1997);
ii) Parkinson’s Disease Quality of Life Questionnaire
(PDQL) (de Boer 1996); or
iii) 36-item Short Form Health Survey (SF-36) (Ware
1992).
3. Adverse events, such as weight loss, measured as the
number of participants with an adverse event associated with the
intervention.
Secondary outcomes
1. PD motor impairment measured using a validated scale
other than the UPDRS subscale Part III (Fahn 1987), such as the
Unified Dyskinesia Rating Scale (UDysRS) (Goetz 2008)
2. Non-motor outcomes measured using validated scales
including UPDRS Part I (Fahn 1987), and Non Motor
Symptoms Questionnaire (NMSQuest) (Chaudhuri 2008)
3. Activities of Daily Living measured using scales such as the
UPDRS Part II (Fahn 1987), and Schwab and England Activities
of Daily Living (SEADL) (Schwab 1969)
4. Psychological outcomes such as dementia and depression
measured using validated scales, for example, the Mattis
Dementia Rating Scale (DRS) (Mattis 1976), or the
Montogomery-Asberg Depression Rating Scale (MADRS)
(Montgomery 1979)
These primary and secondary outcomes address key disease aspects
identified as important by patients and clinicians; the outcomes
classified as relating to participation, mobility and motor func-
tioning were considered to be the most important (Hammarlund
2012), and are assessed using UPDRS Parts I and III respectively.
We will report outcomes measured at the end of the intervention
phase and, if data are available, at least three months post comple-
tion of the intervention. Reporting one or more of the outcomes
listed will not be an inclusion criterion for trials considered for
this review.
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Search methods for identification of studies
Electronic searches
To identify studies considered for inclusion in this review, we
have developed detailed search strategies for each database we will
search.We will assess non-English language papers, translate them
as necessary and evaluate them for inclusion.
Databases to be searched
We will search the following databases from inception for pub-
lished trials in any language:
1. Cochrane Movement Disorders Group trials register;
2. Cochrane Central Register of Controlled Trials
(CENTRAL; the Cochrane Library) (Appendix 1);
3. MEDLINE (OVID) (1946 to present) (Appendix 2);
4. Embase (1974 to present) (Appendix 3).
Searching other resources
We will search the following clinical trials registers:
1. WHO Portal (covers ClinicalTrials.gov; ISRCTN;
Australian and New Zealand Clincal Trial Registry; Chinese
Clinical Trial Register; India Clinical Trials Registry; German
Clinical Trials Register; Iranian Registry of Clinical Trials; Sri
Lanka Clinical Trials Registry; The Netherlands National Trial
Register): www.who.int/trialsearch;
2. UK Clinical Trials Gateway: www.ukctg.nihr.ac.uk/
default.aspx.
We will handsearch the abstracts of the 16th to 21st International
Congresses of the Parkinson’s Disease and Movement Disorders
conference (2012 to 2017) and the meeting abstracts from the
Association of British Neurology (2012 to 2017). As this therapy
is relatively new, we are handsearching the more recent conference
proceedings. We will screen reference lists of included trials and
review articles.
We will cross-check the reference lists of both selected and poten-
tially eligible studies for additional studies to be included.
Data collection and analysis
Selection of studies
We will merge the results of our searches and remove duplicates.
Two review authors will independently screen titles and abstracts
of studies identified by our search for potential inclusion in the
review. We will search for full-text reports of all potentially rele-
vant studies remaining after the initial assessment, and two review
authors will independently assess these for inclusion in the review.
We will resolve any disagreements between the two authors by
consulting a third author. If any posters or conference abstracts
are considered potentially relevant, we will seek full-text reports
of the study and, if unsuccessful, we will contact study authors to
seek further information. Where English translations for studies
published in another language are not available at the screening
stage, we will obtain full-text reports and translate them initially
using an electronic translator. We will exclude studies according
to a hierarchy based on the inclusion criteria, that is, wrong study
design, wrong patient population and wrong comparator. We will
record the reason for study exclusion as the first criterion not met.
We will present reasons for excluding full-text reports in the ’Char-
acteristics of excluded studies’ table. We will produce a PRISMA
flow chart showing how we selected our studies for inclusion in
the review (Liberati 2009).
Data extraction and management
Two review authors will independently extract data from included
studies using a standard data extraction form thatwewill customise
for this review. We will pilot test the form.We will extract the data
detailed below.
1. Publication details
2. Study eligibility criteria
3. Study details e.g. aim, study design, randomisation method,
study location, start and end dates, ethics approval
4. Participant characteristics e.g. number of participants, age,
sex, diagnostic criteria, study setting, baseline measurements
5. Description of intervention and comparator e.g. duration
of treatment, timing, delivery, number of participants
randomized to groups
6. Outcome data e.g. numerical data such as means and
standard deviations, instruments used to assess outcomes of
interest, time points of outcome assessment, withdrawals
7. Data on any relevant reported biomarkers
8. Funding sources and any conflicts of interest for authors
We will compare the extracted data and we will resolve any dis-
agreements by consensus or by deferment to a third review au-
thor. One review author will input the data into Review Manager
5 (RevMan 2014), and these will be checked for accuracy by a
second review author.
Assessment of risk of bias in included studies
Two review authors will independently assess each included study
for risk of bias using the Cochrane tool for assessing risk of bias,
as outlined in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We will assess the risk of bias by
examining the following six domains.
1. Random sequence generation (checking for possible
selection bias): we plan to assess the method used to generate the
allocation sequence as being at: low risk of bias (any truly
random process, e.g. random number table; computer random
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number generator); unclear risk of bias (method used to generate
sequence not clearly stated). We will exclude studies using a non-
random process (e.g. odd or even date of birth; hospital or clinic
record number).
2. Allocation concealment (checking for possible selection
bias): we will assess the method used to conceal allocation to
interventions prior to assignment to determine whether
intervention allocation could have been foreseen in advance of,
or during recruitment, or changed after assignment. We will
assess the methods as being at: low risk of bias (e.g. telephone or
central randomisation; consecutively numbered sealed opaque
envelopes); unclear risk of bias (method not clearly stated); or
high risk of bias (e.g. open list).
3. Blinding of participants and personnel (checking for
possible performance bias): we will assess the methods used to
blind study participants and personnel from knowledge of which
intervention a participant received. We will assess the methods as
being at: low risk of bias (study states that it was blinded and
describes the method used to achieve blinding, such as identical
tablets matched in appearance or smell, or a double-dummy
technique); unclear risk of bias (study states that it was blinded,
but does not provide an adequate description of how this was
achieved). We will consider studies that are not double-blind as
being at a high risk of bias.
4. Blinding of outcome assessment (checking for possible
detection bias): we plan to assess the methods used to blind study
participants and outcome assessors from knowledge of which
intervention a participant received. We will assess the methods as
being at: low risk of bias (study has a clear statement that
outcome assessors were unaware of treatment allocation, and
ideally describes how this was achieved); unclear risk of bias
(study states that outcome assessors were blind to treatment
allocation, but lacks a clear statement on how it was achieved).
We will consider studies where outcome assessment is not
blinded as having a high risk of bias.
5. Selective reporting (checking for reporting bias): we aim to
assess whether reported primary and secondary outcome
measures were prespecified in a protocol. If the trial protocol is
available from a trial registry, the reported outcomes should be
consistent with those listed in the protocol if the protocol was
registered before or at the time the trial began. We will assess
selective reporting as being at: low risk of bias (studies reporting
primary and secondary outcomes as specified in the original
protocol); high risk of bias (not all prespecified outcomes
reported, or only for certain data collection time points).
6. Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data): we will assess the methods used to deal with
incomplete data as being at: low risk (< 10% of participants did
not complete the study and/or used ‘baseline observation carried
forward’ analysis); unclear risk of bias (used ’last observation
carried forward’ analysis); high risk of bias (used ’completer’
analysis).
We will resolve any disagreements by discussion or by deferment
to a third review author. We will present our judgements in the
’Risk of bias’ tables for each study and we will provide statements
to justify our decisions, and appropriate quotes from the reports
to support our decisions. We will provide figures summarising the
risk of bias for all included studies.
Measures of treatment effect
Continuous data
We will analyse these data based on the mean, standard deviation
(SD) and number of participants assessed for both the intervention
and comparison groups to calculate mean difference (MD) and
95% confidence interval (CI). If more than one study measures
the same outcome using different validated scales, we intend to
calculate a standardised mean difference (SMD), standard devia-
tion (SD) and 95% CI.We will calculate SMD as the difference in
mean outcome between groups divided by the pooled SD of both
groups. We will use change from baseline scores for continuous
data.
Dichotomous data
We will analyse these data based on the number of events and the
number of participants assessed in the intervention and compari-
son groups. We will use these data to calculate the risk ratio (RR)
and 95% CI.
Unit of analysis issues
The unit of analysis will be the study participant with PD. For
studies with more than two arms, we will include only those arms
that meet the inclusion criteria of the review. We will analyse data
on an intention-to-treat basis. In cases where multiple interven-
tion groups of interest are present, we will combine all arms into
a single pair-wise comparison, using the Review Manager 5 calcu-
lator (RevMan 2014), using the methods suggested by Cochrane
(Higgins 2011).
Dealing with missing data
Where data are missing we will attempt to contact study authors
to obtain missing data. We will make two attempts to contact
authors. We will examine reports of studies with missing data and,
where possible, we will report reasons for missing data.
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Assessment of heterogeneity
Where we are able to undertake a meta-analysis, we will assess het-
erogeneity using the I² statistic that is included in the forest plot of
a Cochrane Review. We will regard a level of heterogeneity above
50% as substantial or high as explained in Cochrane Handbook for
Systematic Reviews of Interventions Section 9.5.2 (Higgins 2011).
If heterogeneity exists, we will examine study reports to identify
possible reasons for it. If there are sufficient studies, we will un-
dertake subgroup analysis according to possible identified reasons
for heterogeneity.
Assessment of reporting biases
If we are able to pool 10 or more trials in a single analysis, we plan
to create and examine a funnel plot to explore possible small study
and publication biases. We will test for asymmetry using Egger’s
test (Egger 1997). Where protocols are available we will compare
outcomes reported in published trial reports with those listed in
trial protocols to assess reporting bias.
Data synthesis
Where two or more studies report the same outcome, and are
sufficiently similar in terms of treatments and participants, we
will undertake meta-analyses using fixed-effect models. We will
report pooled effectmeasures for dichotomous outcomes using the
Mantel-Haenszel methods, and the inverse variance method for
continuous outcomes. If there is considerable heterogeneity that
cannot readily be explained, we will use random-effects models.
Where it is not possible to pool the findings from studies in ameta-
analysis, we will present the results of each study and provide a
narrative synthesis of findings. We will perform statistical analysis
using Review Manager 5 (RevMan 2014).
Subgroup analysis and investigation of heterogeneity
If sufficient data are available we will conduct the following sub-
group analyses:
1. severity of PD: defined as severe, moderate or mild as
scored on UDPRS subscale Part III (Fahn 1987);
2. clinical subtypes: tremor dominant, mixed, akinetic/rigid;
3. different dosages of GLP-1 receptor agonists;
4. different durations of treatment.
Sensitivity analysis
If we have sufficient studies we will repeat the analyses while ex-
cluding studies with a high risk of bias, for example, due to a lack
of blinding.
Quality of the evidence
Independently, two reviews authors will assess the quality of
the evidence for the three primary outcomes using the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) approach (Schünemann 2013). We will use methods
and recommendations as described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
To ensure the consistency and reproducibility of GRADE judge-
ments, we will assess key outcomes using the criteria below for
each of the five domains.
1. Study limitations: if a study suffers from major limitations,
such as lack of blinding, these are likely to result in a biased
assessment of the intervention effect.
2. Indirectness of the evidence: this may occur when the
review intervention of interest is not compared directly with
comparators of interest, or when trials that meet the inclusion
criteria address a restricted version of the review question in
terms of participants, intervention, comparator or outcomes.
3. Consistency of effect: studies may show differing estimates
of effects, and thus we must look for explanations for
heterogeneity.
4. Imprecision of results: this occurs if included studies have
few participants or events and large confidence intervals.
5. Publication bias: this occurs if investigators do not report
studies, usually those with no effect, or outcomes, typically
harmful ones or those showing no effect.
The GRADE system uses the following criteria for assigning grade
of evidence:
1. high: we are very confident that the true effect lies close to
that of the estimate of the effect;
2. moderate: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of
effect, but there is a possibility that it is substantially different;
3. low: our confidence in the effect estimate is limited; the
true effect may be substantially different from the estimate of the
effect;
4. very low: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
We plan to downgrade the GRADE rating by one (- 1) or two (-
2) levels if we identify:
1. serious (- 1) or very serious (- 2) limitations to study quality;
2. important inconsistency (- 1);
3. some (- 1) or major (- 2) uncertainty about directness;
4. imprecise or sparse data (- 1);
5. a high probability of reporting bias (- 1).
We will provide reasons for our decisions regarding the grading of
the quality of evidence.
’Summary of findings’ table
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We will create a ‘Summary of findings’ table to summarize the
key results of the three primary outcomes: PDmotor impairment,
health-related quality of life, and adverse events.
We will present our assessment of the quality of the evidence in
this table. We will use GRADEpro software to prepare the table
(GRADEpro 2015), importing the data from Review Manager 5
(RevMan 2014).
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 Parkinson Disease:TI,AB,KY
#2 Parkinson*:TI,AB,KY
#3 #1 OR #2
#4 MESH DESCRIPTOR Glucagon-Like Peptide 1 EXPLODE ALL TREES WITH QUALIFIERS AA,AG
#5 ((glucagon like peptide* or GLP 1 or GLP1) ADJ3 (analog* or agonist*)):TI,AB,KY
#6 (exenatide or AC 2993 or ITCA 650):TI,AB,KY
#7 (liraglutide or NN 2211 or NN2211 or NNC 90 1170 or NNC90 1170):TI,AB,KY
#8 (albiglutide or GSK 716155):TI,AB,KY
#9 (elsiglutide):TI,AB,KY
#10 (lixisenatide or AVE 0010):TI,AB,KY
#11 (dulaglutide or LY2189265 or LY 2189265):TI,AB,KY
#12 (taspoglutide or BIM 51077 or BIM51077 or ITM 077 or ITM077 or R 1583 or R1583 or RO 5073031 or RO5073031):
TI,AB,KY
#13 (semaglutide or NN 9535 or NN9535):TI,AB,KY
#14 (teduglutide or ALX 0600 or ALX0600):TI,AB,KY
#15 OR/#4-#14
#16 #3 and #15 in Trials
10GLP-1 receptor agonists for Parkinson’s disease (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 2. MEDLINE search strategy
#1 randomized controlled trial.pt.
#2 controlled clinical trial.pt.
#3 randomized.ab.
#4 placebo.ab.
#5 clinical trials as topic.sh.
#6 randomly.ab.
#7 trial.ti.
#8 1 or 2 or 3 or 4 or 5 or 6 or 7
#9 animals.mh. not humans.mh.
#10 #8 not #9
#11 Parkinson Disease.mh.
#12 Parkinson*.ti,ab.
#13 #11 or #12
#14 exp Glucagon-Like Peptide 1/aa,ag [Analogs & Derivatives, Agonists]
#15 ((glucagon like peptide* or GLP 1 or GLP1) adj3 (analog* or agonist*)).tw.
#16 (exenatide or AC 2993 or ITCA 650).tw.
#17 (liraglutide or NN 2211 or NN2211 or NNC 90 1170 or NNC90 1170).tw.
#18 (albiglutide or GSK 716155).tw.
#19 (elsiglutide).tw.
#20 (lixisenatide or AVE 0010).tw.
#21 (dulaglutide or LY2189265 or LY 2189265).tw.
#22 (taspoglutide or BIM 51077 or BIM51077 or ITM 077 or ITM077 or R 1583 or R1583 or RO 5073031 or RO5073031).tw.
#23 (semaglutide or NN 9535 or NN9535).tw.
#24 (teduglutide or ALX 0600 or ALX0600).tw.
#25 OR/14-24
#26 #10 and #13 and #25





#5 1 or 2 or 3 or 4
#6 Parkinson*.ti,ab.
#7 Parkinson Disease/exp
#8 6 or 7
#9 ((glucagon like peptide* or GLP 1 or GLP1) adj3 (analog* or agonist*)).tw.
#10 (exenatide or AC 2993 or ITCA 650).tw.
#11 (liraglutide or NN 2211 or NN2211 or NNC 90 1170 or NNC90 1170).tw.
#12 (albiglutide or GSK 716155).tw.
#13 (elsiglutide).tw.
#14 (lixisenatide or AVE 0010).tw.
#15 (dulaglutide or LY2189265 or LY 2189265).tw.
#16 (taspoglutide or BIM 51077 or BIM51077 or ITM 077 or ITM077 or R 1583 or R1583 or RO 5073031 or RO5073031).tw.
#17 (semaglutide or NN 9535 or NN9535).tw.
#18 (teduglutide or ALX 0600 or ALX0600).tw.
#19 or/9-37
#20 5 and 8 and 19
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